Perjeta (pertuzumab) is approved for use in combination with Herceptin (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body ...

Perjeta (pertuzumab) is a prescription medicine approved for use in combination with Herceptin (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to ...

The combination of Herceptin, Perjeta, and endocrine therapy without chemotherapy showed promising results in patients with HR+/HER2+ metastatic breast cancer. Adding Kisqali to the treatment regimen ...

Herceptin wasn’t used with Perjeta (pertuzumab) in Herceptin’s studies. But this combination was examined in Perjeta’s studies , which included people whose conditions were treated with ...

The treatment combination of Perjeta (pertuzumab) plus Herceptin (trastuzumab) alone without chemotherapy during first-line treatment, followed by Kadcyla (trastuzumab plus emtansine) as second-line ...

At a three-year follow-up, 94.1% of those receiving both Perjeta and Herceptin hadn’t developed an invasive form of the HER2-positive disease, compared with 93.2% of women taking Herceptin solo ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin ...

Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer over 10 years.

There is no control arm in this trial, but one can use the CLEOPATRA trial as a benchmark where the median PFS for Perjeta in combination with Herceptin and docetaxel was 18.5 months compared to ...

You might also take Herceptin together with other HER2 targeted medicines such as Perjeta (pertuzumab). It’s more likely that you’ll take Herceptin for an early stage cancer if your tumor is ...

Roche said that its work with BIG and other trial partners had enabled studies such as HERA and APHINITY, which have reportedly led to Perjeta and Herceptin becoming standard-of-care treatments.

Genentech, a member of the Roche Group, today announced new data from the Phase III FeDeriCa study which showed the investigational fixed-dose combination of Perjeta ® and Herceptin ® with ...